What one share of Allogene Therapeutics holds
We are a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. We are developing a pipeline of “off-the-shelf” T cell product candidates that are designed to target and kill cancer cells in patients or eliminate pathogenic autoreactive cells in patients with autoimmune disorders.
Allogene Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.65 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.40 |
| Cash and investments | $0.11 |
| Book value | $1.26 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | — | −$7.31 | $0.11 | −$1.65 | $0.00 | — |
| 2019 | — | −$1.83 | $0.50 | −$1.86 | $0.00 | $5.06 |
| 2020 | — | −$2.63 | $0.55 | −$1.50 | $0.00 | $7.21 |
| 2021 | — | −$1.34 | $0.16 | −$1.52 | $0.00 | $6.49 |
| 2022 | $0.00 | −$2.38 | $0.04 | −$1.58 | $0.00 | $4.62 |
| 2023 | $0.00 | −$2.09 | $0.01 | −$1.52 | $0.00 | $3.04 |
| 2024 | $0.00 | −$1.32 | $0.00 | −$1.03 | $0.00 | $1.99 |
| 2025 | $0.01 | −$0.87 | $0.00 | −$0.68 | $0.00 | $1.28 |
Common questions about Allogene Therapeutics
How much does one share of Allogene Therapeutics earn?
Over the last 12 months, Allogene Therapeutics lost $0.65 for each share.
Does Allogene Therapeutics pay a dividend?
Allogene Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Allogene Therapeutics’s book value per share?
Allogene Therapeutics’s book value is $1.26 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Allogene Therapeutics have?
Each share of Allogene Therapeutics has $0.11 of cash and investments, as of June 30, 2026.
What is Allogene Therapeutics’s free cash flow per share?
−$0.40 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Allogene Therapeutics bought back shares?
Allogene Therapeutics’s share count rose about 662% from 2018 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.